|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||92.49 - 97.70|
|52 Week Range||26.02 - 98.70|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2019 - Oct 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||85.00|
Zai Lab Limited (ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the China National Medical Products Administration (NMPA) granted Innovative Medical Device Designation for Optune, a Tumor Treating Fields delivery system that uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth and causing affected cancer cells to die. “We are excited that Optune has been granted the Innovative Device Designation as it will allow our team to accelerate dialogue with the NMPA and bring us closer to commercializing Optune in China,” said Dr. Samantha Du, Founder and CEO of Zai Lab.
On CNBC's "Mad Money Lightning Round," Jim Cramer said eBay Inc (NASDAQ: EBAY ) is going to have a great quarter. He believes it's going to be able to sell StubHub at a much bigger price than ...
This is an amazing company," said Jim Cramer during last night's Lightning Round of his popular Mad Money program. In this daily bar chart of NVCR, below, we can see that prices made a low in November and a retest in December before starting a significant rally into early August. The daily On-Balance-Volume (OBV) line shows an initial rise from late December to late February but then the next four months are mostly flat before another rising in July.
Novocure (NVCR) announced today that it will participate in three upcoming investor conferences. Pritesh Shah, Novocure’s Chief Commercial Officer, will participate in the Wedbush PacGrow Healthcare Conference on August 14, 2019, in New York City. Additionally, Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in the 2019 Wells Fargo Securities Healthcare Conference on September 4, 2019, in Boston.
NovoCure (NVCR) delivered earnings and revenue surprises of 85.71% and 6.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference
Novocure (NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. The announcement by CMS follows an announcement earlier this morning by the durable medical equipment (DME) Medicare Administrative Contractors (MACs) that a final local coverage determination (LCD) providing coverage, effective September 1, 2019, of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) has been established. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields.
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure (NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) effective September 1, 2019. The final LCD and a summary response to comments are available in the U.S. Centers for Medicare & Medicaid Services (CMS) coverage database. “We are extremely pleased that CMS has established coverage of Optune for patients with newly diagnosed GBM and that many of the restrictions originally proposed were removed in response to public comment,” said Bill Doyle, Novocure’s Executive Chairman.
Capturing a powerful move in a short time is one of the main goals of swing trading. Novocure stock provides an example of a recent swing trade.
CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 187,500 shares of NVCR on 06/28/2019 at an average price of $62.15 a share.
Novocure announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended June 30, 2019, at 8 a.m.